Bromometric analysis of Lamotrigine, Minoxidil and Cefixime
A. Aboul-Kheir, Hanaa Saleh, Magda M. El-Henawee and M.N. Sharf El-Din
Analytical Chemistry Department, Faculty of
Pharmacy, Zagazig University, Zagazig,
Egypt.
*Corresponding
Author E-mail: dr_moh0300@yahoo.com
ABSTRACT:
Two spectrophotometric methods are described for determination
of Lamotrigine, Minoxidil
and Cefixime in bulk and pharmaceutical dosage forms
using insitu generated bromine as oxidizing agent and
either methyl orange or methylene blue as chromogenic agents. Drugs are treated with known excess of
bromine and residual unreacted bromine is determined
by treating with fixed amount of either methyl orange and measuring absorbance
at 508 nm or methylene blue and measuring absorbance
at 667 nm for minoxidil and lamotrigine
and at 747 nm for cefixime. The amount of bromine
reacted corresponds to the amount of each drug. Calibration curves were linear
over ranges of 4.0 – 30.0, 0.5 – 4.0 and 0.5 – 5.0 µg.ml-1 for lamotrigine, minoxidil and cefixime,
respectively in case of methyl orange and of
5.0 – 40.0, 0.5 – 7.0 and 2.0 – 5.5 µg.ml-1 for lamotrigine, minoxidil and cefixime, respectively in case of methylene
blue. The methods were satisfactory applied for the determination of drugs in
both bulk and pharmaceutical forms and results were compared statistically with
reference methods.
INTRODUCTION:
Lamotrigine is (6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine).(1)
It blocks voltage-gated sodium channels in presynaptic
neurons and inhibits the release of glutamate. It displays neuroprotective
effects in various models and is a clinically useful anti-epileptic agent.(2)
Various analytical techniques have been employed for the determination of lamotrigine in pure and dosage forms including HPLC,(3-7)
gas chromatography,(8,9) thin-layer chromatography,(10)
capillary electrophoresis,(11,12) spectrophotometry,(13-15)
adsorptive stripping voltammetry,(16) selective
membrane electrode,(17) Immunofluorimetric
assay(18) and radioimmunoassay.(19)
Minoxidil is
(6-(piperidin-1-yl)pyrimidine-2,4-diamine 3-oxide).(1) It is a
peripheral vasodilator and it is used in scalp preparations for hair loss.(2)
Several methods were reported for the determination of minoxidil
in pure and dosage forms including HPLC,(20-22) Gas-chromatography,(23) capillary isotachophoresis,(24)
derivative spectrophotometry,(25) Integrated flow
injection-solid phase spectrophotometry,(26)
spectrophotometry(27-31) and differential
pulse polarography.(32)
Cefixime is [(6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-yl)-2-[(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic
acid trihydrate].(1) It is generally
classified as third generation cephalosporin antibiotic and is given by mouth
in the treatement of susceptible infections including
gonorrhoea, otitis media, pharyngitis, lower respiratory tract infections such as
bronchitis and urinary tract infections.(2) It is reported to be
determined through many techniques including HPLC,(33-37) HPTLC(38), capillary zone
electrophoresis(39,40), voltammetry(41,42),
selective membrane electrode(43), Spectrophotometry(33,44-47)
and spectrofluorimetry( 47,48).
Minoxidil
Lamotrigine
Cefixime
2. EXPERIMENTAL:
2.1.
Apparatus
All of the spectrophotometric measurements were carried out using a
Shimadzu UV-1800 with matched 1 cm quartz cells. A Lutron
digital pH-meter was used for pH adjustment.
2.2.
Materials and reagents
All solvents and
reagents were of analytical grade and double distilled water was used throughout
the work. Lamotrigine (Delta Pharm,
10th of Ramadan city, Egypt) working solution 5 µg.ml-1 was
prepared by dissolving in least amount of DMF then completing to volume with
distilled water.
Minoxidil ((Delta Pharm, 10th
of Ramadan city, Egypt) working solution 5 µg.ml-1 was prepared by
dissolving in least amount of methanol then completing to volume with distilled
water.
Cefixime (Sigma Pharmaceuticals, Kwesna,
Egypt) working solution 5 µg.ml-1 was prepared by dissolving in
distilled water. 5 M HCl (El-Nasr Chemicals, Egypt)
was prepared by diluting 225 ml of concentrated HCl
(36%) to 500 ml.
Methyl Orange (Fluka, Switzerland) 20 mg/100 ml dissolved in and completed
to 100 ml mark with distilled water and filtered (stable for 2 weeks at least).
Methylene blue (Fluka,
Switzerland) 20 mg/100 ml dissolved in 20 ml methanol then completed to 100 ml
with distilled water (stable for 2 weeks at least).
Bromide/bromate stock solution were prepared by dissolving 100 mg
of potassium bromate (Winlab,
England) and 1.0 gm of potassium bromide (Winlab,
England) in 100 ml distilled water (stable for 10 days at least). Working
solution was freshly prepared daily by diluting 2.5 ml of stock solution to 100
ml with distilled water.
2.3.
Pharmaceutical preparations
The following
available pharmaceutical preparations were analyzed
Lamotrine® tablets labeled to contain 25 mg per
tablet. Batch No. MT1960807 (Multi Apex
Pharm. Company, Badr City).
Ximacef® Capsules labeled to contain 400 mg cefixime per capsule. Batch No.90640 (Sigma
Pharmaceuticals, Kwesna, Egypt).
Performa® lotion
5% Batch # 80163 (Delta Pharm Company, 10th of
Ramadan, Egypt).
2.3.
Procedure
2.3.1.
General spectrophotometric procedure for
determination of Lamotrigine, Minoxidil and Cefixime.
2.3.1.1. Lamotrigine
To 0.5 ml bromate working solution add 0.1-2 ml (0.5 to 20 µg/ml)
drug then acidify using 1 ml 5 M HCl and stand for 5
minutes, add 1.0 ml dye working solution then stand for 5 minutes and complete
to 10 ml mark with distilled water then measure absorbance against reagent
blank similarly prepared at 667 nm or 508 nm for methylene
blue or methyl orange, respectively.
2.3.1.2. Minoxidil
Mix 1.0 ml of bromate working solution with 0.1- 2 ml (0.5 to 20 µg/ml)
drug in 10 ml measuring flask and add 1 ml 5 M HCl
stand for 5 minutes, add 1 ml dye working solution and stand for 5 minutes and
complete to 10 ml mark with distilled water then measure absorbance against
blank similarly prepared at 667nm or 508 nm for methylene
blue or methyl orange, respectively.
2.3.1.3. Cefixime
In 10 ml
measuring flask place 1 ml bromate working solution,
0.1- 2 ml (0.5 to 20 µg/ml) drug, acidify with 4 ml 5 M HCl,
stand for 15 minutes then add 0.5 ml dye and wait for 5 minutes before diluting
to 10 ml with distilled water and measure absorbance at 747 nm or 508 nm for methylene blue or methyl orange, respectively against
reagent blank similarly prepared.
In the stated
methods calibration graph was prepared by plotting absorbance versus
concentration of drug and the concentration of the unknown was computed from
the regression equation derived from the Beer’s law data.
2.3.2.
Procedure for pharmaceutical preparations
For Lamotrine® tablets: 10
tablets were crushed and a weight equivalent to two tablets was taken,
extracted three successive times with 20 ml DMF, filtered into 100 ml measuring
flask and then completed to volume with distilled water. Then follow the same
procedures described for determination as in authentic sample.
For
Performa® lotion: Transfer 1.0 ml of lotion to 50 ml measuring
flask then complete to mark with distilled water. Then follow the same
procedures described for determination as in authentic sample.
For Ximacef® capsules contents of 10 capsules were obtained and
weight equivalent to 500 µg was taken, extracted three successive times with
methanol, filtered into 100 ml measuring flask and then completed to volume
with distilled water. Then follow the same procedures described for
determination as in authentic sample.
2.3.3 Reference
method procedure for Lamotrigine determination
(49) (according to Delta Pharm.) Amount equivalent to 10 mg was extracted with methanol
three times, filtered, washed into 100 ml measuring flask and completed to
volume with dist. Water. Known volumes were taken into 10 ml measuring flask
and completed to volume with 0.1 M HCl then
absorbance was measured at 267 nm against blank.
3. RESULTS AND DISCUSSION:
The proposed spectrophotometric methods are indirect and are based on
the determination of the residual bromine (insitu
generated) after allowing the reaction between each drug and a measured amount
of bromine to be complete. The surplus bromine was determined by reacting it
with a fixed amount of either methylene blue or
methyl orange dye. The methods rely on the bleaching action of bromine on the
dyes, the discoloration being caused by the oxidative destruction of the dyes. Lamotrigine, minoxidil or cefixime when added in increasing amounts to a fixed amount
of insitu generated bromine, consumes the latter
proportionately and there occurs a concomitant fall in the concentaration
of bromine. When a fixed amount of dye is added to the decreasing amounts of
bromine, a concomitant increase in the concentration of dye results.
Consequently, a proportional increase in the absorbance at the respective λmax is observed with increasing
concentration of each drug.
The insitu generation of bromine is carried out using a mixture of potassium bromide and
potassium bromate in presence of 5 M HCl according to the
following equation:
5Br-
+ BrO3- + 6H+ 3Br2
+ 3H2O
3.1.
Absorption spectra
The resulting
absorption spectra are due to the red colour of
residual unoxidized methyl orange at 508 nm (fig 1)
or blue colour of residual unoxidized
methylene blue at 667 nm for lamotrigine
and minoxidil and at 747 for cefixime
as both minoxidil and lamotrigine
are analyzed in presence of 1.5 ml 5N HCL while cefixime
is analyzed in presence of 4 ml 5N HCl (Fig 3).
Fig 1: Absorption spectra of methyl orange in
presence of 5µg/ml Lamotrigine(A), 5µg/ml Minoxidil
(B) and 5µg/ml Cefixime (C).
Methylene blue
exhibited two types of absorption spectra according to different volumes
of hydrochloric acid. In low HCl concentration (1 ml 5N HCl
and complete to 10 ml) it exhibits peak maximum at 666 nm and in high HCl concentration (4 ml 5N HCl
and complete to 10 ml) it exhibits peak maximum at 745 nm. A detailed
investigation regarding different forms of methylene
blue was carried out(52) proving the reasons for variation in
absorption maximum at different acidities. Fig 2
Fig 2: Absorption spectra of methylene blue against blank in weak acidic medium (A) and in strong acidic medium (B)
Fig 3: Absorption spectra of methylene blue in presence of 20µg/ml Lamotrigine(A), 10µg/ml
Minoxidil(B) and 10µg/ml Cefixime
(C)
3.2. Effect
of dye concentration
Experiments were
performed to found appropriate dye concentrations by stabilizing other
experimental conditions and using different volumes of dyes and results
illustrated that increasing dye volume above 1ml in case of lamotrigine
and minoxidil does not result in change of absorption
while only 0.6 ml were sufficient in case of Cefixime.(Fig
4 and 5)
Fig.(4) Effect of methyl
orange concentration on absorption
intensity.
Fig.(5) Effect of methylene blue
concentration on absorption intensity.
3.3. Effect
of Acidity
Different acids
were tested as a medium for bromine generation including sulphuric
acid, hydrochloric acid, nitric acid and phosphoric acid. Hydrochloric acid
produced the most precise and accurate results. Therefore, 5 M HCl was used throughout experiments and it was found that
0.5-2 ml 5 M HCl is the appropriate acid volume for
determination of Lamotrigine and increasing HCl volume above 2 ml result in a rapid decrease in
absorption. While, 1.0-4.0 ml 5 M HCl is suitable for
Minoxidil analysis. And 2.0-5.0 ml 5 M HCl is the appropriate volume in case of Cefixime. And this indicates that the specified acid
concentration for bromination reaction was not
critical.
3.3. Effect
of time
Time required to
brominates and oxidize the drug before addition of dye and time required to
irreversibly oxidize dye after its addition was studied throughout different
experiments using both of dyes. It was found that the bromination
reaction was found to be complete in 5 minutes for lamotrigine
and minoxidil and in 15 minutes in case of cefixime and after oxidation time, contact times up to 60
min had been examined and no further bromination was
detected. A contact time of 5 minutes was necessary for the bleaching of the
dye colour by the residual bromine and the colour of both dye solutions remain stable for at least two
hours after mixing with the reaction mixture.
Method
validation
The developed
methods were validated according to international conference of harmonization
guidelines. (51) The
linearity range of absorbance as a function of drug concentration (Table 1) provide
an accurate measure of sensitivity of reagents used. Calibration curves have
correlation coefficients (r) higher than 0.999 indicating good linearity. The
accuracy of the methods were determined by investigating the recovery of drugs
at concentration levels covering the specified range (three replicates of each
concentration). The results showed excellent recoveries (table 2).Intraday
precision was evaluated by calculating standard deviation (SD) of five
replicate determinations using the same solution containing pure drug at three
different levels. The SD values revealed the high precision of the methods
(values vary from 0.89 to 1.12). For inter-day reproducibility on a day-to-day
basis, a series was run, in which the standard drug solution at three levels
was analyzed each for five days. The day-to-day SD values were in the range of
1.09-1.84. The limit of detection (LD) and limit of quantitation
(LQ) were calculated.
Table (1) Analytical parameters for the determination
of mentioned drugs using proposed
methods.
|
Parameters |
Methyl orange |
Methylene blue |
||||
|
Lamotrigine |
Minoxidil |
Cefixime |
Lamotrigine |
Minoxidil |
Cefixime |
|
|
Bromate mixture volume, ml |
0.5 |
1.0 |
1.0 |
0.5 |
1.0 |
1.0 |
|
Dye volume, ml |
1.0 |
1.0 |
0.5 |
1.0 |
1.0 |
0.5 |
|
Time before dye addition, min |
5 |
5 |
15 |
5 |
5 |
15 |
|
λmax, nm |
508 |
508 |
508 |
667 |
667 |
747 |
|
Beer's law limits µg/ml |
4.0 – 30.0 |
0.5 – 4.0 |
0.5 – 5.0 |
5.0 – 40.0 |
0.5 – 7.0 |
2.0 – 5.5 |
|
Regression equation* |
|
|
|
|
|
|
|
Intercept |
0.0471 |
-0.1653 |
-0.043 |
0.043 |
0.0614 |
-0.569 |
|
Slope |
.035 |
0.353 |
0.278 |
0.0264 |
0.123 |
0.334 |
|
Correlation Coefficient |
0.99978 |
0.99976 |
0.99988 |
0.99986 |
0.99969 |
0.99966 |
*A = a + b
C, where C = concentration of drug in μg mL-1, A
= absorbance, a = intercept, b = slope.
According to
ICH guidelines, the obtained values indicated high sensitivity of the proposed
methods. The robustness of the methods was evaluated by making small changes in
the volume of acid [method A (methyl orange 1.0 , 1,5 and 2.0 ml of 5 M HCl and methylene blue 2.0, 2.5
and 3.0 ml 5M HCl] and contact time and the effect of
the changes was studied on the percent recovery of the drug. The changes had
negligible influence on the results as revealed by small SD values (≤
1.93)
Application
Some
Pharmaceutical formulations containing stated drugs have been successfully
analyzed by the proposed methods. Excipients did not show interference. Results
obtained were compared to those obtained by applying reference methods and
Student’s t-test and F-test were performed for comparison. Results are shown in
table 3, 4 and 5.
Table(2). Results
of the analysis for determination of mentioned drugs using proposed methods.
|
Parameters |
Methyl
orange |
||||||||
|
Lamotrigine |
Minoxidil |
Cefixime |
|||||||
|
Taken µg/ml |
Found µg/ml |
Recovery % |
Taken µg/ml |
Found µg/ml |
Recovery % |
Taken µg/ml |
Found µg/ml |
Recovery % |
|
|
|
4 |
3.99 |
99.92 |
0.5 |
0.51 |
102.23 |
0.5 |
0.50 |
100.90 |
|
|
5 |
5.05 |
101.09 |
1 |
1.01 |
100.73 |
1 |
0.98 |
98.31 |
|
|
8 |
7.94 |
99.26 |
1.5 |
1.49 |
99.29 |
1.5 |
1.50 |
100.33 |
|
|
10 |
10.11 |
101.13 |
2 |
2.01 |
100.27 |
2 |
1.99 |
99.54 |
|
|
12 |
12.11 |
100.95 |
2.5 |
2.49 |
99.61 |
2.5 |
2.51 |
100.21 |
|
|
15 |
14.89 |
99.24 |
3 |
2.97 |
98.98 |
3 |
3.02 |
100.78 |
|
|
20 |
19.89 |
99.44 |
4 |
4.03 |
100.68 |
3.5 |
3.52 |
100.47 |
|
|
24 |
23.83 |
99.30 |
|
|
|
4 |
3.99 |
99.70 |
|
|
25 |
24.92 |
99.67 |
|
|
|
4.5 |
4.47 |
99.34 |
|
|
30 |
30.26 |
100.87 |
|
|
|
5 |
5.01 |
100.27 |
|
Mean |
|
|
100.09 |
|
|
100.26 |
|
|
99.98 |
|
±S D |
|
|
0.82 |
|
|
1.10 |
|
|
0.78 |
|
±RSD |
|
|
0.82 |
|
|
1.10 |
|
|
0.78 |
|
±SE |
|
|
0.37 |
|
|
0.49 |
|
|
0.35 |
|
Variance |
|
|
0.68 |
|
|
1.21 |
|
|
0.61 |
|
Slope |
|
|
0.03 |
|
|
0.35 |
|
|
0.28 |
|
LD |
|
|
0.049 |
|
|
0.064 |
|
|
0.053 |
|
LQ |
|
|
0.164 |
|
|
0.214 |
|
|
0.176 |
|
S.S. |
|
|
0.05 |
|
|
0.01 |
|
|
0.005 |
|
Molar absorbitivity L.Mol-1.cm-1 |
1.0164 X104 |
4.8556 X104 |
1.02405X105 |
||||||
|
Parameters |
Methylene blue |
||||||||
|
Lamotrigine |
Minoxidil |
Cefixime |
|||||||
|
Taken µg/ml |
Found µg/ml |
Recovery % |
Taken µg/ml |
Found µg/ml |
Recovery % |
Taken µg/ml |
Found µg/ml |
Recovery % |
|
|
|
5 |
5.08 |
101.58 |
0.5 |
0.51 |
101.88 |
2 |
1.99 |
99.50 |
|
|
10 |
10.08 |
100.81 |
1 |
0.96 |
95.67 |
2.5 |
2.48 |
99.32 |
|
|
15 |
15.01 |
100.05 |
1.5 |
1.49 |
99.56 |
3 |
2.99 |
99.73 |
|
|
20 |
19.86 |
99.29 |
2 |
2.01 |
100.69 |
3.5 |
3.53 |
100.97 |
|
|
25 |
24.90 |
99.59 |
2.5 |
2.53 |
101.05 |
4 |
4.03 |
100.78 |
|
|
30 |
29.79 |
99.29 |
3 |
2.97 |
99.11 |
4.5 |
4.47 |
99.30 |
|
|
35 |
35.24 |
100.69 |
5 |
5.09 |
101.75 |
5 |
4.99 |
99.85 |
|
|
40 |
40.05 |
100.14 |
6 |
5.98 |
99.70 |
5.5 |
5.50 |
100.03 |
|
|
|
|
|
7 |
6.96 |
99.40 |
|
|
|
|
Mean |
|
|
100.18 |
|
|
99.87 |
|
|
99.93 |
|
±S D |
|
|
0.81 |
|
|
1.88 |
|
|
0.64 |
|
±RSD |
|
|
0.81 |
|
|
1.88 |
|
|
0.64 |
|
±SE |
|
|
0.36 |
|
|
0.84 |
|
|
0.28 |
|
Variance |
|
|
0.66 |
|
|
3.53 |
|
|
0.40 |
|
Slope |
|
|
0.03 |
|
|
0.12 |
|
|
0.33 |
|
LD |
|
|
0.47 |
|
|
0.133 |
|
|
0.071 |
|
LQ |
|
|
1.56 |
|
|
0.444 |
|
|
0.236 |
|
S.S. |
|
|
0.06 |
|
|
0.01 |
|
|
0.01 |
|
Molar absorbitivity L.Mol-1.cm-1 |
7.518 X103 |
3.3422 X104 |
6.6928 X104 |
||||||
Table (3). Statistical analysis of results obtained by the
proposed methods applied on Performa® lotion compared with comparison method
|
Parameters |
Methyl orange |
Methylene blue |
Comparison
method(29) |
|
N |
6 |
8 |
6 |
|
Mean Recovery |
99.9 |
100.1 |
99.9 |
|
Variance |
0.79 |
0.48 |
1.0 |
|
±S.D. |
0.89 |
0.70 |
1.0 |
|
±R.S.D. |
0.89 |
0.70 |
1.0 |
|
±S.E. |
0.36 |
0.25 |
0.5 |
|
Student-t(50) |
0.0146 (2.02) |
0.435 (1.90) |
|
|
F-test(50) |
1.27 (5.05) |
2.08 (4.17) |
|
Table (4). Statistical analysis of results obtained by the
proposed methods applied on Lamotrine® tablets
compared with reference method
|
Parameters |
Methyl
orange |
Methylene blue |
Comparison
method(49) |
|
N |
6 |
6 |
6 |
|
Mean Recovery |
99.87 |
99.99 |
100.1 |
|
Variance |
0.789 |
0.94 |
2.2 |
|
±S.D. |
0.89 |
0.97 |
1.5 |
|
±R.S.D. |
0.89 |
0.97 |
1.5 |
|
±S.E. |
0.36 |
0.40 |
0.7 |
|
Student-t(50) |
0.326
(2.02) |
0.1534
(2.02) |
|
|
F-test(50) |
2.79
(5.05) |
2.34
(5.05) |
|
Table (5). Statistical analysis of results obtained by the
proposed methods applied on Ximacef® tablets compared
with reference method
|
Parameters |
Methyl
orange |
Methylene blue |
Comparison
method(44) |
|
N |
7 |
6 |
6 |
|
Mean Recovery |
100.4 |
99.96 |
99.93 |
|
Variance |
1.33 |
0.51 |
0.63 |
|
±S.D. |
1.15 |
0.71 |
0.79 |
|
±R.S.D. |
1.15 |
0.71 |
0.79 |
|
±S.E. |
0.44 |
0.29 |
0.35 |
|
Student-t(50) |
0.865
(1.94) |
0.069
(2.02) |
|
|
F-test(50) |
2.11
(4.39) |
1.235
(5.05) |
|
CONCLUSION:
Two new spectrophotometric methods for determination of lamotrigine, minoxidil and cefixime have been developed based on insitu
generation of bromine and using methyl orange or methylene
blue as chromogenic agents. They proved to be rapid,
accurate, sensitive and reproducible.
REFERENCES:
1. British
Pharmacopoeia, HM Stationery Office, London, UK, PA, 2007,
2. Martindale:
The Complete Drug Reference, Pharmaceutical Press;35 edition (2007)
3. Bompadre, S. Tagliabracci, A. Battino, M. Giorgetti, R.
Determination of lamotrigine in whole blood with on
line solid phase extraction. J Chromatogr B, 2008, 863 (1), 177-180.
4. Budakova, L. Brozmanove, H. Grundmann, M. Fischer, J. Simultaneous determination of
antiepileptic drugs and their two active metabolites by HPLC. J sep sci, 2008, 31 (1), 1-8.
5. Vermeij, T. A. C. Edelbroek, P.
M. Robust isocratic high performance liquid chromatographic method for
simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B, 2007, 857 (1), 40-46.
6. Saracino, M. A. Bugamelli, F.
Conti, M. Amore, M. Raggi, M. A. Rapid HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma. J Sep Sci, 2007, 30 (14), 2249-2255
7. Doig, M. V. Clare, R. A. Use of thermospray
liquid chromatography - mass spectrometry to aid in the identification of
urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr, 1991,
554 (1-2), 181-189
8. Dasgupta, A. Hart, A. P. Lamotrigine
analysis in plasma by gas chromatography-mass spectrometry after conversion to
a t-butyldimethylsilyl derivative. J Chromatogr B, 1997, 693 (1), 101-107
9. Watelle, M. Demedts, P. Franck,
F. De Deyn, P. P. Wauters,
A. Neels, H. Analysis of the antiepileptic phenyltriazine compound lamotrigine
using gas chromatography with nitrogen-phosphorus detection. Ther Drug Monit, 1997, 19 (4), 460-464
10. Patil, K. M. Bodhankar, S. L.
High-performance thin-layer chromatographic determination of lamotrigine in serum. J Chromatogr
B, 2005, 823 (2), 152-157
11. Theurillat, R. Kuhn, M. Thormann,
W. Therapeutic drug monitoring of lamotrigine using
capillary electrophoresis. Evaluation of assay performance and quality
assurance over a 4-year period in the routine arena. J Chromatogr, 2002,
979 (1-2), 353-368
12. Shihabi, Z. K. Oles, K. S. Serum lamotrigine analysis by capillary electrophoresis. J Chromatogr B, 1996,
683 (1), 119-123
13. Alizadeh, N. Khakinahad, R. Jabbari, A. Spectrophotometric determination of lamotrigine in pharmaceutical preparations and urine by
charge-transfer complexation. Pharmazie, 2008, 63(11),
791-795.
14. Youssef,
N. Taha,
E. Development and validation of spectrophotometric, TLC and HPLC methods for the
determination of lamotrigine in presence of its
impurity. Chem Pharm Bull
(Tokyo). 2007 ;55 (4):541.
15. RS
Talekar, AS Dhake, DB Sonaje, V K. Mourya.
Spectrophotometric determination of lamotrigine.
Indian J Pharm sci. 2000; 62(1): 51-2
16. Burgoa Calvo, M. E. Dominguez Renedo, O. Arcos Martinez, M. J. Determination of lamotrigine by adsorptive stripping voltammetry
using silver nanoparticle-modified carbon screen-printed electrodes. Talanta, 2007,
74 (1), 59-64
17. Gupta,
V. K. Singh, A. K. Gupta, B. Development of membrane electrodes for selective
determination of some antiepileptic drugs in pharmaceuticals, plasma and urine.
Anal Bioanal Chem, 2007,
389 (6), 2019-2028
18. Sailstad, J. M. Findlay, J. W. A. ,Immunofluorimetric
assay for lamotrigine (lamictal)
in human plasma.” Ther
Drug Monit, 1991, 13 (5), 433-442
19.
Biddlecombe, R. A. Dean, K. L.Smith,
C. D. Jeal, S. C. Validation of a radioimmunoassay
for the determination of human plasma concentrations of lamotrigine. J Pharmaceut
Biomed, 1990, 8 (8-12), 691-694
20. Huang,
T. H. Garceau, M. E. Ramstad, T. Stehle,
R. G. Rapid determination of trace amounts of minoxidil
in hamster skin follicles with various formulations using narrow-bore
LC/EC. J Pharmaceut
Biomed, 2005, 38 (3), 532-536
21. Zarghi, A. Shafaati, A. Foroutan, S. M. Khaddam, A. Rapid determination of minoxidil
in human plasma using ion-pair HPLC. J Pharmaceut Biomed, 2004, 36 (2), 377-379
22. Gagliardi,-L Amato,-A Turchetto,-L.
Tonelli,-D. Simultaneous determination of minoxidil and tretinoin in
pharmaceutical and cosmetic formulations by reversed-phase HPLC. Anal Lett. 1991 24(10), 1825-1835
23. Kaniewska,-T. Kublin,-E. Kwiatkowska,-B. Gas-chromatographic determination of minoxidil in serum. Farm. Pol., 1987, 43 (9),
508-511
24. Fanali, S. Cristalli, M. Catellani, P.
Determination of minoxidil in pharmaceutical forms by
capillary isotachophoresis. J Chromatogr,
1987, 405, 385-388
25. Mahrous,-MS. Abdel-Khalek,-MM. Beltagy,-YA. Simultaneous quantitation
of minoxidil and tretinoin
[retinoic acid] in magistral and pharmaceutical
preparations by first-derivative spectrophotometry.
Anal Lett. 1992;
25(9): 1673-1686
26. Ruiz-Medina,
A. Fernandez-de Cordova, M. L. Molina-Diaz, A. Integrated flow
injection-solid phase spectrophotometric
determination of minoxidil. Talanta, 1999,
50 (2), 277-282
27. Sastry,-CSP. Sailaja,-A. Rao,-TT. Krishna,-DM. Extractive spectrophotometric
determination of some antihypertensive agents with Supracen
violet 3B. Indian-Drugs. Aug 1992; 29(11): 473-477
28. Sastry,-CSP. Sailaja,-A. Rao,-TT. Krishna,-DM. Note on the estimation of minoxidil in pharmaceutical preparations by ion-pair
extraction method. Indian-Drugs. 1992;
29(11): 473-477
29. Arcos,
J. Garcia, B.; Munguia, A. Lopez Palacios, J.
Kauffmann, J. M. Partiarche, G. J. Spectrophotometric
and electro-analytical study of minoxidil. Anal Lett. 1991, 24 (3), 357-376
30. Sastry, C. S. P. Sailaja, A. Thirupathi Rao, T. Suryanarayana, M. Simple spectrophotometric
method for the determination of minoxidil. Microchem j. 1991, 44 (3), 268-271
31. El-Sayed Mahrous, M. Three methods
for the quantitative determination of minoxidil. Anal
Lett. 1991, 24 (11), 2017-2032
32. Amankwa, L. Chatten, L. G. Pons,
S. Electrochemical studies on minoxidil and its
determination in tablets by differential pulse polarography.
The Analyst, 1983, 108 (1291), 1221-1226
33. Shah,
P. B.; Pundarikakshudu, K.; Journal of
AOAC International, 2006, 89 (4), 987-994
34. Meng, F.; Chen, X. Y.; Zeng, Y. L.; Zhong,
D. F.; J.Chromatography B: Anal. Technol. Biomed. Life Sci., 2005, 819 (2),
277-282
35. Manna,
L.; Valvo, L.; Chromatographia
, 2004, 60 (11-12), 645-649
36. Gonzalez-Hernandez,
R.; Nuevas-Paz, L.; Soto-Mulet, L.; Lopez-Lopez, M.; Hoogmartens, J.; Journal of Liquid Chromatography
and Related Technologies, 2001, 24 (15), 2315-2324
37. Nahata, M. C.; Journal of Liquid Chromatography and
Related Technologies, 1991, 14 (20), 3755-3759
38. Eric-Jovanovic, S.; Agbaba, D.;
Zivanov-Stakic, D.; Vladimirov,
S.; J. Pharm. and Biomed. Anal, 1998, 18 (4-5), 893-898
39. Solangi, A. R.*; Memon, S.
Q.; Khuhawar, M. Y.; Bhanger, M. I.; Acta Chromatographica, 2007 (19), 81-96
40. Honda, S.; Taga, A.; Kakehi,
K.; Koda, S.; Okamoto, Y.; J. Chromatography, 1992, 590
(2), 364-368
41. Golcu, A.; Dogan, B.; Ozkan, S. A.; Talanta,
2005, 67 (4), 703-712
42. Reddy,
T. M.; Sreedhar, M.; Reddy, S. J.;
J. Pharm. and Biomed. Anal, 2003, 31 (4), 811-818
43. Ganjali, M. R.; Naji, L.;
Poursaberi, T.; Shamsipur,
M.; Haghgoo, S.; Analytica
Chimica Acta, 2003, 475
(1-2), 59-66
44. Shankar,
D. G.; Sushma, K.; Lakshmi,
R. V.; Reddy, M. N.; Murthy, T. K.; Rao
Srinivasa, Y.; Indian Drugs, 2001, 38
(12), 617-619
45. Al-Momani, I. F.; J. Pharm. and Biomed. Anal, 2001, 25
(5-6), 751-757
46. El
Walily, A. F. M.; Gazy,
A. A. K.; Belal, S. F.; Khamis, E. F.; Spectroscopy Letters, 2000, 33
(6), 931-948
47. El-Walily, A. F. M.; Gazy, A.
A.; Belal, S. F.; Khamis,
E. F.; J. Pharm. and Biomed. Anal, 2000, 22 (2), 385-392
48. Bebawy, L. I.; El Kelani,
K.; Abdel Fattah, L.; J. Pharm. and Biomed. Anal, 2003, 32
(6), 1219-1225
49. personal
communication with Delta Pharm.(10th of Ramadan, Egypt)
50. Modern
Analytical Chemistry, David Harvey,
McGraw-Hill Companies, first edition, 2002
51. Guidance
for Industry : Q2B of Analytical
Procedures; Methodololgy: International
Conference of Harmonization (ICH). Nov.
1996 (http:/ www.fda.gov/eder/guidance /1320fnl.pdf)
52. M.
John Plater, ARKIVOC 2003 (i)
37-42
Received on 12.02.2012 Accepted on 28.02.2012
© Asian Pharma
Press All Right Reserved
Asian J. Pharm.
Ana. 2(1): Jan.-Mar. 2012;
Page 22-28